My Creative Rapamycin Solution Works While You Take A Nap!

Non-hematological toxicity was assessed according to the NCI Common Toxicity Criteria version 3.0 [http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf]. Thirteen patients from four participating centers were enrolled and treated between February 2010 and September 2012. Pretreatment characteristics are shown in Table 1. The median age was 60 years (range 53�C74). Median number of previous lines of immunochemotherapy was 3 (range 1�C5). All patients had been pretreated with rituximab, eight (62%) had upfront fludarabine, cyclophosphamide, rituximab (FCR), while in five patients (38%) the first line treatment consisted of rituximab plus chlorambucil or cyclophosphamide, vincristine, prednisone (R-CVP). These five patients had been considered too old or unfit to receive first-line FCR by the treating physicians. Subsequent lines of treatment included alemtuzumab in five patients, bendamustine http://www.selleck.cn/products/AP24534.html in three, while http://www.selleckchem.com/products/Rapamycin.html one patient had relapsed after alloHCT (number 10, see Table 1). Five patients (38%) were refractory to previous chemoimmunotherapy, including four fludarabine-refractory patients according to the NCI definition (31% of the whole cohort, 50% of patients previously treated with FCR). At study entry, median time since CLL first diagnosis was 34 months (range 7�C117), median absolute lymphocyte count was 46,000/mmc (range 4,100�C382,000), Binet stage was B or C and all tested patients had elevated ��2-microglobulin. In line with the aggressive clinical behavior of included patients, all showed unmutated IGHV status. FISH analysis revealed the presence of 17p- in six (46%), 11q- in four (31%), or both deletions in three (23%). These abnormalities were accompanied by at least one additional chromosomal gain or deletion in four (Table 1). Nine patients (69%) completed the planned four treatment http://www.selleckchem.com/products/jq1.html cycles. Four patients discontinued after